DEFA14A: TuHURA Biosciences and Kineta, Inc. Announce Non-Binding Letter of Intent for Potential Acquisition of KVA12123

TuHURA Biosciences and Kineta, Inc. have entered into a non-binding letter of intent for TuHURA to potentially acquire Kineta's KVA12123 VISTA inhibiting antibody.

Summary

• Kineta, Inc. and TuHURA Biosciences have signed a non-binding letter of intent for a potential transaction where TuHURA would acquire the rights to Kineta's KVA12123, a VISTA inhibiting antibody.
• TuHURA paid Kineta $5 million in July 2024 for exclusivity rights and an additional $300,000 in October 2024 to extend the agreement, which will be credited towards the acquisition if it proceeds.
• TuHURA is planning a Phase 3 trial for its IFx-2.0 cancer therapy, targeting a first half of 2025 initiation, and has secured a Special Protocol Assessment (SPA) agreement with the FDA.
• The potential acquisition of KVA12123 would add a Phase 2 ready asset to TuHURA's pipeline, with potential synergies across their existing technologies.
• TuHURA has also made key management hires, including a Vice President of Clinical Operations and a Head of Quality Assurance, to support their development programs.
• TuHURA completed a $31 million financing in connection with its merger with Kintara, which is expected to fund operations into the second half of 2025.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting progress in clinical development and potential acquisitions. However, the non-binding nature of the letter of intent and the inherent risks in drug development temper the overall sentiment.

Positives

• The potential acquisition of KVA12123 would add a promising Phase 2 ready asset to TuHURA's pipeline.
• TuHURA's IFx-2.0 Phase 3 trial is progressing with a Special Protocol Assessment (SPA) agreement with the FDA, potentially accelerating approval.
• The company has secured $31 million in funding, expected to support operations into the second half of 2025.
• Key management hires in clinical operations and quality assurance are expected to strengthen the company's execution capabilities.
• TuHURA is exploring novel technologies to overcome resistance to cancer immunotherapy, addressing a significant unmet need.

Negatives

• The agreement between TuHURA and Kineta is currently a non-binding letter of intent, and the acquisition is not guaranteed.
• The acquisition of KVA12123 is subject to further diligence and negotiations.
• The company is seeking licensing opportunities for REM-001, indicating a potential shift in focus away from this asset.

Risks

• The potential acquisition of KVA12123 may not be completed, or may not be completed on favorable terms.
• The Phase 3 trial for IFx-2.0 may not be successful, or may not lead to regulatory approval.
• The company's cash resources may not be sufficient to fund all of its planned operations.
• There are risks associated with the development of novel therapies, including clinical trial failures and regulatory hurdles.
• The company is subject to risks related to the competitive landscape in the immuno-oncology space.

Future Outlook

TuHURA is targeting the initiation of a Phase 3 trial for IFx-2.0 in the first half of 2025 and the potential acquisition of KVA12123, with Phase 2 trials for the acquired asset planned for the second half of 2025 if the acquisition is completed. The company expects its current financing to fund operations into the second half of 2025.

Management Comments

• James Bianco, M.D., President and Chief Executive Officer of TuHURA, commented on the progress made towards corporate objectives, including the SPA agreement with the FDA for the IFx-2.0 Phase 3 trial.
• Dr. Bianco also highlighted the potential acquisition of KVA12123 as a synergistic addition to their pipeline.
• Dr. Bianco expressed excitement about strengthening the leadership team with the appointments of Peter O'Neill and Michael Krsulich.

Industry Context

This announcement reflects the ongoing trend in the immuno-oncology space of companies seeking to combine novel therapies and technologies to overcome resistance to existing treatments. The potential acquisition of KVA12123 by TuHURA is an example of companies consolidating assets to build stronger pipelines and address unmet needs in cancer treatment.

Comparison to Industry Standards

• The development of IFx-2.0 as an adjunctive therapy to Keytruda aligns with the industry trend of combining checkpoint inhibitors with other immunotherapies to enhance efficacy.
• The use of a Special Protocol Assessment (SPA) with the FDA is a common strategy to de-risk clinical trials and accelerate the approval process, similar to other companies in the biotech sector.
• The focus on tumor microenvironment modulation through bi-specific ADCs and PDCs is a growing area of interest in the industry, with several companies exploring similar approaches.
• The acquisition of a Phase 2 ready asset like KVA12123 is a common strategy for companies looking to expand their pipelines and accelerate their development timelines, similar to other biotech acquisitions.

Management Changes

Stakeholder Impact

• Shareholders of both Kineta and TuHURA will be impacted by the potential acquisition, with the possibility of share dilution or value creation.
• Employees of both companies may experience changes in their roles and responsibilities as a result of the potential transaction.
• Patients may benefit from the development of new cancer therapies, including IFx-2.0 and KVA12123.
• The potential acquisition could impact the competitive landscape in the immuno-oncology space.

Next Steps

• TuHURA and Kineta will continue negotiations to reach a definitive agreement for the acquisition of KVA12123.
• TuHURA plans to initiate a Phase 3 trial for IFx-2.0 in the first half of 2025.
• TuHURA will continue to advance its other pipeline programs, including IFx-3.0 and tumor microenvironment modulators.
• TuHURA will seek licensing opportunities for REM-001.

Key Dates

Keywords

TuHURA Biosciences, Kineta, KVA12123, VISTA inhibitor, IFx-2.0, immunotherapy, cancer, Phase 3 trial, acquisition, merger, FDA, Special Protocol Assessment, oncology